If the FDA changes guidance, restricts, or removes access to any compounded preparation, Vesta will discontinue that preparation in alignment with federal regulation
The insurer released the non-peer-reviewed data to inform decisionmakers and the public about how these two wildly popular weight-loss drugs are being used and to "paint a clearer picture of what makes somebody successful," said Razia Hashmi, vice president for clinical affairs at Blue Cross Blue Shield
doi: 10.1016/j.tcb.2022.02.009 50 ZhuJBerisaMSchworerSQinWCrossJRThompsonCB
Secondary outcomes The secondary outcomes are as follows: type 2 diabetes, glucose, HbA1c, insulin, lipid profile (LDL-cholesterol, HDL-cholesterol, triglycerides and apolipoprotein B), systolic blood pressure, diastolic blood pressure, and body mass index (BMI), which are well-established risk factors for CVD in clinical practice, or recently identified to be related to CVD in MR, such as apolipoprotein B [30, 31]
Adverse events in clinical trials must be reported through the trial sponsor's pharmacovigilance processes